子類別 期刊論文 [327/330] 圖書 [1/1] 會議論文/會議摘要 [115/179] 鄰近社群 于重元 [19/19] 劉柯俊 [85/98] 劉滄梧 [119/125] 劉界元(2003-2010) [3/3] 夏和雄(1996-2012) [26/31] 夏興國 [51/54] 姜乃榕 [82/94] 常慧如 [39/44] 張俊彥 [234/254] 張光裕 [69/79] 張憶壽 [103/106] 張文祥 [52/53] 張書銘 [89/91] 彭汪嘉康(1996-2007) [120/126] 施能耀 [37/43] 李家惠 [29/29] 李岳倫 [48/49] 林素芳 [32/32] 楊奕馨 [41/42] 江士昇 [88/90] 沈哲宏 [14/16] 洪文俊 [88/88] 莊雙恩 [82/91] 蔡坤志 [32/34] 蔡慧珍 [66/71] 蘇勇曄 [40/40] 蘇振良 [24/25] 郭靜娟 [71/76] 陳尚鴻 [45/48] 陳振陽 [72/72] 陳美霞(2002-2009) [1/1] 陳詩政 [2/2] 陳雅雯 [38/39] 黃智興 [55/55] 黃道揚 [26/26] 丁兆治(2000-2004) [5/5] 其他 [464/471] 劉敏(1996-2007) [60/62] 劉玫英(2004-2006) [2/2] 吳成文(1996-2008) [53/55] 曾思文(1997-2007) [4/4] 李冠德(1997-2004) [4/6] 林景太(1999-2007) [5/5] 楊文光(1996-1999) [21/21] 王全正(1996-2003) [4/4] 莊聲宏(1997-2004) [11/11] 詹宗晃(2000-2008) [2/2] 賴基銘(2004-2008) [41/47] 阮麗蓉(2000-2006) [6/7] 陳俊叡(2003-2007) [6/6] 馬彥英(1997-1999) [1/1] 黃奇英(2005-2007) [9/10] 社群統計 近3年內發表的文件:74(14.51%) 含全文筆數:443(86.86%) 文件下載次數統計 下載大於0次:443(100.00%) 下載大於100次:424(95.71%) 檔案下載總次數:176904(3.30%) 最後更新時間: 2024-11-28 13:36 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 Pan-Asian adapted ESMO clinical pra... Nivolumab plus chemotherapy in pati... Survival of advanced/recurrent gast... Topiramate suppresses peri-infarct ... A phase 1 study of biweekly nab-pac... Plain language summary of the FOENI... Outcomes of post-immunotherapy dura... Durvalumab or placebo plus gemcitab... Impact of previous S-1 treatment on... Chromatin remodeling-related PRDM1 ...

跳至: (選擇年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目226-250 / 510. (共21頁) << < 5 6 7 8 9 10 11 12 13 14 > >> 每頁顯示[10|25|50]項目

日期	題名	關聯
2017-09	Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37)	Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 671P.
2017-09	A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)	Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 617O.
2017-08	Overexpressed fatty acid synthase in gastrointestinal stromal tumors: Targeting a progression-associated metabolic driver enhances the antitumor effect of imatinib	Clinical Cancer Research. 2017 Aug;23(16):4908-4918.
2017-08	A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo	Cancer Chemotherapy and Pharmacology. 2017 Aug;80(2):307-315.
2017-07	A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17	Oncotarget. 2017 Jul;8(27):44121-44130.
2017-06-26	Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI +/- 5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy	Annals of Oncology. 2017 Jun 26;28(Suppl. 3):Abstract number PD - 018.
2017-06-26	CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) +/- 5-fluorouracil and leucovorin (5FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy	Annals of Oncology. 2017 Jun 26;28(Suppl. 3):Abstract number PD-017.
2017-05-04	Chemotherapy in the management of pancreatic cancer	Pancreatic Cancer: With Special Focus on Topical Issues and Surgical Techniques. 2017 May 4:387-419.
2017-05	Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: A Q-TWiST analysis	British Journal of Cancer. 2017 May;116(10):1247-1253.
2017-05	The prognostic value of baseline neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM	Journal of Clinical Oncology. 2017 May;35:Meeting Abstract e15795.
2017-05	A phase I dose escalation study of SCBO1A, a micro tubular inhibitor with vascular disrupting activity, in patients with advanced solid tumors refractory to standard therapy	Journal of Clinical Oncology. 2017 May;35(Suppl. 15):Meeting Abstract 2531.
2017-02	Nanoliposomal irinotecan in the clinical practice guideline for metastatic pancreatic cancer: Applicability to clinical situations	Journal of Clinical Oncology. 2017 Feb;35(6):689-690.
2017-02	The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21)	Journal of Pathology. 2017 Feb;241(3):420-433.
2017-02	Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells	Oncology Reports. 2017 Feb;37(2):969-978.
2017-02	A phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer	Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):417.
2017-02	Efficacy and safety of liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPO	Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):303.
2017-02	Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial	Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):2.
2017-02	Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-FU/LV	Journal of Clinical Oncology. 2017 Feb;35(4):Meeting Abstract 293.
2017-01	Expressions of the CagA protein and CagA-signaling molecules predict H. pylori-dependence of early-stage gastric DLBCL	Blood. 2017 Jan;129(2):188-198.
2016-12	The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan	Asia-Pacific Journal of Clinical Oncology. 2016 Dec;12(4):396-402.
2016-12	Efficacy and safety of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02, BAX-2398) in patients with metastatic pancreatic cancer in Asia: A subgroup analysis of the phase 3 NAPOLI-1 Study	Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 221PD.
2016-12	Effects of nal-IRI (MM-398) +/- 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1	Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 242P.
2016-12	Sequential use of everolimus and sunitinib in treating WHO grade 1 and 2 pancreatic neuroendocrine tumors-retrospective multi-center study in Taiwan	Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 420P.
2016-11-21	A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors	BMC Cancer. 2016 Nov 21;16:Article number 907.
2016-11	Role of epigenetic regulator EHMT2 in the regulation of gemcitabine resistance in pancreatic cancer	Journal of Gastroenterology and Hepatology. 2016 Nov;31(Suppl. 3):245.

顯示項目226-250 / 510. (共21頁) << < 5 6 7 8 9 10 11 12 13 14 > >> 每頁顯示[10|25|50]項目